{"id":4814,"date":"2025-08-12T10:24:37","date_gmt":"2025-08-12T10:24:37","guid":{"rendered":"https:\/\/www.dsru.org\/?post_type=abstract&#038;p=4814"},"modified":"2026-07-23T15:30:36","modified_gmt":"2026-07-23T15:30:36","slug":"abstract-267-incidence-of-major-and-clinically-relevant-non-major-bleeding-in-patients-prescribed-rivaroxaban-results-from-the-rose-study","status":"publish","type":"abstract","link":"https:\/\/www.dsru.org\/abstract\/abstract-267-incidence-of-major-and-clinically-relevant-non-major-bleeding-in-patients-prescribed-rivaroxaban-results-from-the-rose-study\/","title":{"rendered":"Abstract 267: Incidence Of Major And Clinically-Relevant Non-Major Bleeding In Patients Prescribed Rivaroxaban: Results From The ROSE Study"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">A. Evans 1, 2, M. Davies 1, 2, L. Wise1, S. Shakir1, 2*<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">1Drug Safety Research Unit, Southampton, 2University of Portsmouth, Portsmouth, United Kingdom<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Background<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The ROSE (Rivaroxaban Observational Safety Evaluation) Specialist Cohort Event Monitoring (SCEM) study was conducted to monitor the safety and use of rivaroxaban for Stroke Prevention in patients (pts) with non-valvular AF (SPAF) and the prevention and\/or treatment of Deep Vein Thrombosis and\/or Pulmonary Embolism (DVT\/PE) in the secondary care setting in England and Wales. The study complements another study conducted in primary care by focusing on the acute phase of treatment.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Objectives<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">To estimate the incidence of major and clinically-relevant non-major (CRNM) bleeding (ISTH definition) in patients prescribed rivaroxaban for the first time for SPAF and DVT\/PE indications.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Methods<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Patients were identified through speciality groups (2013-2016), supported by UK Clinical Research Networks. Risk factors for bleeding (HAS-BLED) and bleeding outcomes were collected via detailed questionnaires completed by hospital specialists at baseline and \u2265 12 weeks. Summary descriptive statistics and 12 week incidence risk and rate (per 100 patient years) were calculated.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Results<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The cohort consisted of 2542 pts including 965 patients with AF (38.0% of cohort; median age 76 years [IQR 69, 83], 517 [53.6%] male), median HAS-BLED score 2 (IQR 1-3) (moderate risk of major bleeding) and 1532 patients with DVT\/PE (60.3% of cohort; median age 63 years [IQR 48, 73], 836 [54.6%] male), median HAS-BLED score 1 (IQR 0-2) (low risk of major bleeding).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">AF group: Rate: Major + CRNM bleeding 28.2 (95% CI 21.0, 37.1; n=51), Major Bleed 5.5 (95% CI 2.6-10.1; n=10), CRNM bleeding 22.7 (95% CI 16.3-30.8; n=41).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Major Bleed risk in pre-specified sites: gastrointestinal (GI) (0.2%; n=2), urogenital (UG) (0.2%; n=2), intracranial (IC) (0.2%; n=2) and all other critical organ (excluding IC) (0.1%; n=1).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">DVT\/PE group: Rate: Major + CRNM bleeding 36.2 (95% CI 29.4, 44.1; n=98), Major Bleed 8.3 (95% CI 5.3, 12.5; n=23), CRNM bleeding 27.6 (95% CI 21.7, 34.6; n=75).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Major Bleed risk in pre-specified sites: GI (0.7%; n=11), UG (0.3%; n=5), IC (0.1%; n=1) and all other critical organ (excluding IC) (0.0%; n=0).<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Conclusions<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The incidence of major bleeding was low and no new safety concerns were raised. Unique aspects of this study design enabled collection of highly detailed information from cardiologists, faciliating accurate calculation of risk scores and the application of clinical trial outcome definitions, in a real-word setting. Differences in methodology between this and other study designs prevents meaningful comparison.<\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false},"categories":[45],"tags":[],"class_list":["post-4814","abstract","type-abstract","status-publish","hentry","category-isop-18th-annual-meeting-geneva-november-2018"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Abstract 267: Rivaroxaban Bleeding Incidence \u2013 ROSE<\/title>\n<meta name=\"description\" content=\"DSRU&#039;s ROSE study abstract on major and clinically relevant bleeding incidence in patients prescribed rivaroxaban for AF and DVT\/PE.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.dsru.org\/abstract\/abstract-267-incidence-of-major-and-clinically-relevant-non-major-bleeding-in-patients-prescribed-rivaroxaban-results-from-the-rose-study\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Abstract 267: Rivaroxaban Bleeding Incidence \u2013 ROSE\" \/>\n<meta property=\"og:description\" content=\"DSRU&#039;s ROSE study abstract on major and clinically relevant bleeding incidence in patients prescribed rivaroxaban for AF and DVT\/PE.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.dsru.org\/abstract\/abstract-267-incidence-of-major-and-clinically-relevant-non-major-bleeding-in-patients-prescribed-rivaroxaban-results-from-the-rose-study\/\" \/>\n<meta property=\"og:site_name\" content=\"DSRU\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DrugSafetyResearchUnit\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-23T15:30:36+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@DSRUDrugSafety\" \/>\n<meta name=\"twitter:label1\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n\t<meta name=\"twitter:label2\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data2\" content=\"ashleigh barton\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.dsru.org\\\/abstract\\\/abstract-267-incidence-of-major-and-clinically-relevant-non-major-bleeding-in-patients-prescribed-rivaroxaban-results-from-the-rose-study\\\/\",\"url\":\"https:\\\/\\\/www.dsru.org\\\/abstract\\\/abstract-267-incidence-of-major-and-clinically-relevant-non-major-bleeding-in-patients-prescribed-rivaroxaban-results-from-the-rose-study\\\/\",\"name\":\"Abstract 267: Rivaroxaban Bleeding Incidence \u2013 ROSE\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.dsru.org\\\/#website\"},\"datePublished\":\"2025-08-12T10:24:37+00:00\",\"dateModified\":\"2026-07-23T15:30:36+00:00\",\"description\":\"DSRU's ROSE study abstract on major and clinically relevant bleeding incidence in patients prescribed rivaroxaban for AF and DVT\\\/PE.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.dsru.org\\\/abstract\\\/abstract-267-incidence-of-major-and-clinically-relevant-non-major-bleeding-in-patients-prescribed-rivaroxaban-results-from-the-rose-study\\\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.dsru.org\\\/abstract\\\/abstract-267-incidence-of-major-and-clinically-relevant-non-major-bleeding-in-patients-prescribed-rivaroxaban-results-from-the-rose-study\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.dsru.org\\\/abstract\\\/abstract-267-incidence-of-major-and-clinically-relevant-non-major-bleeding-in-patients-prescribed-rivaroxaban-results-from-the-rose-study\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.dsru.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Abstract 267: Incidence Of Major And Clinically-Relevant Non-Major Bleeding In Patients Prescribed Rivaroxaban: Results From The ROSE Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.dsru.org\\\/#website\",\"url\":\"https:\\\/\\\/www.dsru.org\\\/\",\"name\":\"DSRU\",\"description\":\"The UK\u2019s leading pharmacovigilance and pharmacoepidemiology unit.\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.dsru.org\\\/#organization\"},\"alternateName\":\"Drug Safety Research Unit\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.dsru.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.dsru.org\\\/#organization\",\"name\":\"DSRU\",\"alternateName\":\"Drug Safety Research Unit\",\"url\":\"https:\\\/\\\/www.dsru.org\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/www.dsru.org\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.dsru.org\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/cropped-DSRU_Branding.png\",\"contentUrl\":\"https:\\\/\\\/www.dsru.org\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/cropped-DSRU_Branding.png\",\"width\":250,\"height\":115,\"caption\":\"DSRU\"},\"image\":{\"@id\":\"https:\\\/\\\/www.dsru.org\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/DrugSafetyResearchUnit\",\"https:\\\/\\\/x.com\\\/DSRUDrugSafety\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/drug-safety-research-unit\\\/\",\"https:\\\/\\\/www.instagram.com\\\/drugsafetyresearchunit\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Abstract 267: Rivaroxaban Bleeding Incidence \u2013 ROSE","description":"DSRU's ROSE study abstract on major and clinically relevant bleeding incidence in patients prescribed rivaroxaban for AF and DVT\/PE.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.dsru.org\/abstract\/abstract-267-incidence-of-major-and-clinically-relevant-non-major-bleeding-in-patients-prescribed-rivaroxaban-results-from-the-rose-study\/","og_locale":"en_GB","og_type":"article","og_title":"Abstract 267: Rivaroxaban Bleeding Incidence \u2013 ROSE","og_description":"DSRU's ROSE study abstract on major and clinically relevant bleeding incidence in patients prescribed rivaroxaban for AF and DVT\/PE.","og_url":"https:\/\/www.dsru.org\/abstract\/abstract-267-incidence-of-major-and-clinically-relevant-non-major-bleeding-in-patients-prescribed-rivaroxaban-results-from-the-rose-study\/","og_site_name":"DSRU","article_publisher":"https:\/\/www.facebook.com\/DrugSafetyResearchUnit","article_modified_time":"2026-07-23T15:30:36+00:00","twitter_card":"summary_large_image","twitter_site":"@DSRUDrugSafety","twitter_misc":{"Estimated reading time":"2 minutes","Written by":"ashleigh barton"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.dsru.org\/abstract\/abstract-267-incidence-of-major-and-clinically-relevant-non-major-bleeding-in-patients-prescribed-rivaroxaban-results-from-the-rose-study\/","url":"https:\/\/www.dsru.org\/abstract\/abstract-267-incidence-of-major-and-clinically-relevant-non-major-bleeding-in-patients-prescribed-rivaroxaban-results-from-the-rose-study\/","name":"Abstract 267: Rivaroxaban Bleeding Incidence \u2013 ROSE","isPartOf":{"@id":"https:\/\/www.dsru.org\/#website"},"datePublished":"2025-08-12T10:24:37+00:00","dateModified":"2026-07-23T15:30:36+00:00","description":"DSRU's ROSE study abstract on major and clinically relevant bleeding incidence in patients prescribed rivaroxaban for AF and DVT\/PE.","breadcrumb":{"@id":"https:\/\/www.dsru.org\/abstract\/abstract-267-incidence-of-major-and-clinically-relevant-non-major-bleeding-in-patients-prescribed-rivaroxaban-results-from-the-rose-study\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.dsru.org\/abstract\/abstract-267-incidence-of-major-and-clinically-relevant-non-major-bleeding-in-patients-prescribed-rivaroxaban-results-from-the-rose-study\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.dsru.org\/abstract\/abstract-267-incidence-of-major-and-clinically-relevant-non-major-bleeding-in-patients-prescribed-rivaroxaban-results-from-the-rose-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.dsru.org\/"},{"@type":"ListItem","position":2,"name":"Abstract 267: Incidence Of Major And Clinically-Relevant Non-Major Bleeding In Patients Prescribed Rivaroxaban: Results From The ROSE Study"}]},{"@type":"WebSite","@id":"https:\/\/www.dsru.org\/#website","url":"https:\/\/www.dsru.org\/","name":"DSRU","description":"The UK\u2019s leading pharmacovigilance and pharmacoepidemiology unit.","publisher":{"@id":"https:\/\/www.dsru.org\/#organization"},"alternateName":"Drug Safety Research Unit","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.dsru.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/www.dsru.org\/#organization","name":"DSRU","alternateName":"Drug Safety Research Unit","url":"https:\/\/www.dsru.org\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.dsru.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.dsru.org\/wp-content\/uploads\/2022\/01\/cropped-DSRU_Branding.png","contentUrl":"https:\/\/www.dsru.org\/wp-content\/uploads\/2022\/01\/cropped-DSRU_Branding.png","width":250,"height":115,"caption":"DSRU"},"image":{"@id":"https:\/\/www.dsru.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/DrugSafetyResearchUnit","https:\/\/x.com\/DSRUDrugSafety","https:\/\/www.linkedin.com\/company\/drug-safety-research-unit\/","https:\/\/www.instagram.com\/drugsafetyresearchunit\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.dsru.org\/wp-json\/wp\/v2\/abstract\/4814","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.dsru.org\/wp-json\/wp\/v2\/abstract"}],"about":[{"href":"https:\/\/www.dsru.org\/wp-json\/wp\/v2\/types\/abstract"}],"wp:attachment":[{"href":"https:\/\/www.dsru.org\/wp-json\/wp\/v2\/media?parent=4814"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.dsru.org\/wp-json\/wp\/v2\/categories?post=4814"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.dsru.org\/wp-json\/wp\/v2\/tags?post=4814"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}